CAPRICOR THERAPEUTICS, INC. (NASDAQ:CAPR) Files An 8-K Regulation FD Disclosure
Item 7.01
| Regulation FD Disclosure. |
On June 6, 2017, Capricor Therapeutics, Inc., a Delaware
corporation (the Company), posted to the Investors section of the
Companys website at www.capricor.com a corporate
presentation providing an update of the Companys current business
and products (the Corporate Presentation). A copy of the
Corporate Presentation is attached hereto as Exhibit 99.1 and is
incorporated by reference into this Item 7.01 of this Current
Report on Form 8-K.
The information contained in this Current Report on Form 8-K) is
being furnished and shall not be deemed to be filed for the
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), or otherwise subject to the
liabilities of that section and shall not be incorporated by
reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as shall be expressly set
forth by specific reference in such filing.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
| 99.1 |
Capricor Therapeutics, Inc. slide presentation dated June 6, 2017. |
About CAPRICOR THERAPEUTICS, INC. (NASDAQ:CAPR)
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. Its product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction (MI), while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure. CAP-1002 is also being tested in the HOPE-Duchenne Phase I/II clinical study for use in connection with Duchenne muscular dystrophy-related cardiomyopathy. Cenderitide, a dual receptor natriuretic peptide agonist, is being tested in a Phase II clinical study. Exosomes are nano-sized, membrane-enclosed vesicles.
